---
document_datetime: 2025-12-02 05:14:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/buprenorphine-neuraxpharm.html
document_name: buprenorphine-neuraxpharm.html
version: success
processing_time: 0.1201748
conversion_datetime: 2025-12-28 05:03:19.515451
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Buprenorphine Neuraxpharm

[RSS](/en/individual-human-medicine.xml/250698)

##### Authorised

This medicine is authorised for use in the European Union

buprenorphine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Buprenorphine Neuraxpharm](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76622)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Buprenorphine Neuraxpharm is a medicine used to treat dependence on opioid (narcotic) drugs such as heroin or morphine. It is used in adults and adolescents aged 15 years and above who have agreed to be treated for addiction and who are also receiving medical, social and psychological support.

Buprenorphine Neuraxpharm contains the active substance buprenorphine and is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but that it is given in a different way. The reference medicine for Buprenorphine Neuraxpharm is Subutex. Buprenorphine Neuraxpharm is available as a sublingual film (a film to be placed under the tongue), whereas Subutex is available as sublingual tablets or a solution for injection.

Expand section

Collapse section

## How is Buprenorphine Neuraxpharm used?

Buprenorphine Neuraxpharm is given as a film to be placed under the tongue once a day, where it will dissolve in about 10 to 15 minutes.

Treatment should be started by and remain under the supervision of a doctor experienced in the management of opioids dependence/addiction. It is recommended that Buprenorphine Neuraxpharm is used in combination with other interventions for opioid drug dependence.

The medicine can only be obtained by 'special' prescription. This means that because the medicine can be misused or cause addiction, it is used under stricter conditions than normal.

For more information about using Buprenorphine Neuraxpharm, see the package leaflet or contact your doctor or pharmacist.

## How does Buprenorphine Neuraxpharm work?

The active substance in Buprenorphine Neuraxpharm, buprenorphine, is a partial opioid agonist/antagonist. This means that it acts like an opioid drug but less powerfully, and it can therefore be used in a controlled way to help prevent withdrawal symptoms and reduce the urge to misuse other opioids.

## What benefits of Buprenorphine Neuraxpharm have been shown in studies?

Because buprenorphine is a widely used, well-known active substance, its effectiveness is well described in the medical literature. In addition, studies have shown that giving Buprenorphine Neuraxpharm produces similar levels of the active substance in the body as giving Subutex.

## What are the risks associated with Buprenorphine Neuraxpharm?

For the full list of side effects and restrictions with Buprenorphine Neuraxpharm, see the package leaflet.

The most common side effects with Buprenorphine Neuraxpharm (which may affect more than 1 in 10 people) include symptoms of drug withdrawal, such as insomnia (difficulty sleeping), headache, nausea (feeling sick), hyperhidrosis (excessive sweating) and pain.

Buprenorphine Neuraxpharm must not be used in patients with severe respiratory insufficiency (inability to breathe properly) or severe liver problems, and in patients who are intoxicated with alcohol or who are experiencing alcohol withdrawal symptoms.

## Why is Buprenorphine Neuraxpharm authorised in the EU?

The European Medicines Agency considered that the benefits and risks of the active substance, buprenorphine, are well known from the medical literature. Studies have shown that Buprenorphine Neuraxpharm produces sufficient levels of the active substance in people given the medicine. The Agency therefore concluded that the medicine's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Buprenorphine Neuraxpharm?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Buprenorphine Neuraxpharm have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Buprenorphine Neuraxpharm are continuously monitored. Suspected side effects reported with Buprenorphine Neuraxpharm are carefully evaluated and any necessary action taken to protect patients.

## Other information about Buprenorphine Neuraxpharm

Buprenorphine Neuraxpharm received a marketing authorisation valid throughout the EU on 19 December 2024.

Buprenorphine Neuraxpharm : EPAR - Medicine overview

Reference Number: EMA/551021/2024

English (EN) (119.72 KB - PDF)

**First published:** 09/01/2025

[View](/en/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-927)

български (BG) (141.1 KB - PDF)

**First published:**

09/01/2025

[View](/bg/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_bg.pdf)

español (ES) (121.83 KB - PDF)

**First published:**

09/01/2025

[View](/es/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_es.pdf)

čeština (CS) (140.61 KB - PDF)

**First published:**

09/01/2025

[View](/cs/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_cs.pdf)

dansk (DA) (119.22 KB - PDF)

**First published:**

09/01/2025

[View](/da/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.5 KB - PDF)

**First published:**

09/01/2025

[View](/de/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_de.pdf)

eesti keel (ET) (117.39 KB - PDF)

**First published:**

09/01/2025

[View](/et/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_et.pdf)

ελληνικά (EL) (144.7 KB - PDF)

**First published:**

09/01/2025

[View](/el/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_el.pdf)

français (FR) (122.69 KB - PDF)

**First published:**

09/01/2025

[View](/fr/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.67 KB - PDF)

**First published:**

09/01/2025

[View](/hr/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_hr.pdf)

italiano (IT) (121.03 KB - PDF)

**First published:**

09/01/2025

[View](/it/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.43 KB - PDF)

**First published:**

09/01/2025

[View](/lv/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.67 KB - PDF)

**First published:**

09/01/2025

[View](/lt/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_lt.pdf)

magyar (HU) (140.28 KB - PDF)

**First published:**

09/01/2025

[View](/hu/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_hu.pdf)

Malti (MT) (141.73 KB - PDF)

**First published:**

09/01/2025

[View](/mt/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_mt.pdf)

Nederlands (NL) (122.29 KB - PDF)

**First published:**

09/01/2025

[View](/nl/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_nl.pdf)

polski (PL) (144.03 KB - PDF)

**First published:**

09/01/2025

[View](/pl/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_pl.pdf)

português (PT) (122.25 KB - PDF)

**First published:**

09/01/2025

[View](/pt/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_pt.pdf)

română (RO) (137.78 KB - PDF)

**First published:**

09/01/2025

[View](/ro/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_ro.pdf)

slovenčina (SK) (142.48 KB - PDF)

**First published:**

09/01/2025

[View](/sk/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.41 KB - PDF)

**First published:**

09/01/2025

[View](/sl/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_sl.pdf)

Suomi (FI) (117.66 KB - PDF)

**First published:**

09/01/2025

[View](/fi/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_fi.pdf)

svenska (SV) (117.92 KB - PDF)

**First published:**

09/01/2025

[View](/sv/documents/overview/buprenorphine-neuraxpharm-epar-medicine-overview_sv.pdf)

Buprenorphine Neuraxpharm : EPAR - Risk Management Plan

English (EN) (533.71 KB - PDF)

**First published:** 09/01/2025

[View](/en/documents/rmp/buprenorphine-neuraxpharm-epar-risk-management-plan_en.pdf)

## Product information

Buprenorphine Neuraxpharm : EPAR - Product information

English (EN) (419.94 KB - PDF)

**First published:** 09/01/2025

**Last updated:** 16/05/2025

[View](/en/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-486)

български (BG) (468 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/bg/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_bg.pdf)

español (ES) (347.69 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/es/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_es.pdf)

čeština (CS) (462.21 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/cs/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_cs.pdf)

dansk (DA) (380.3 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/da/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_da.pdf)

Deutsch (DE) (427.2 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/de/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_de.pdf)

eesti keel (ET) (363.76 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/et/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_et.pdf)

ελληνικά (EL) (495.21 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/el/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_el.pdf)

français (FR) (411.98 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/fr/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_fr.pdf)

hrvatski (HR) (444.71 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/hr/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_hr.pdf)

íslenska (IS) (402.78 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/is/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_is.pdf)

italiano (IT) (387.81 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/it/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_it.pdf)

latviešu valoda (LV) (453.29 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/lv/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_lv.pdf)

lietuvių kalba (LT) (482.92 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/lt/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_lt.pdf)

magyar (HU) (466.67 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/hu/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_hu.pdf)

Malti (MT) (479.3 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/mt/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_mt.pdf)

Nederlands (NL) (399.52 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/nl/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_nl.pdf)

norsk (NO) (437.05 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/no/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_no.pdf)

polski (PL) (454.52 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/pl/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_pl.pdf)

português (PT) (352.03 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/pt/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_pt.pdf)

română (RO) (470.6 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/ro/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_ro.pdf)

slovenčina (SK) (453.56 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sk/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_sk.pdf)

slovenščina (SL) (419.32 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sl/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_sl.pdf)

Suomi (FI) (367.92 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/fi/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_fi.pdf)

svenska (SV) (393.99 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sv/documents/product-information/buprenorphine-neuraxpharm-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000267606 16/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Buprenorphine Neuraxpharm : EPAR - All authorised presentations

English (EN) (146.34 KB - PDF)

**First published:** 09/01/2025

**Last updated:** 16/05/2025

[View](/en/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-949)

български (BG) (115.81 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/bg/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_bg.pdf)

español (ES) (147.06 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/es/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_es.pdf)

čeština (CS) (109.13 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/cs/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (103.71 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/da/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (105.72 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/de/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (104.13 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/et/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (113.45 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/el/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_el.pdf)

français (FR) (146.82 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/fr/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (109.32 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/hr/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (101.77 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/is/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_is.pdf)

italiano (IT) (148.08 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/it/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (111.34 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/lv/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (110.29 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/lt/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (117.56 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/hu/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (111.54 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/mt/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (151.3 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/nl/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (148.36 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/no/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_no.pdf)

polski (PL) (152.7 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/pl/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_pl.pdf)

português (PT) (148.07 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/pt/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_pt.pdf)

română (RO) (109.93 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/ro/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (109.28 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sk/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (109.66 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sl/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (145.8 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/fi/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (147.09 KB - PDF)

**First published:**

09/01/2025

**Last updated:**

16/05/2025

[View](/sv/documents/all-authorised-presentations/buprenorphine-neuraxpharm-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Buprenorphine Neuraxpharm Active substance buprenorphine hydrochloride International non-proprietary name (INN) or common name buprenorphine Therapeutic area (MeSH) Opioid-Related Disorders Anatomical therapeutic chemical (ATC) code N07BC01

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Substitution treatment of opioid drug dependence, within a comprehensive therapeutic monitoring framework of medical, social and psychological treatment.

Treatment is intended for use in adults and adolescents 15 years of age and older, who have agreed to be treated for addiction.

## Authorisation details

EMA product number EMEA/H/C/006188 Marketing authorisation holder

Neuraxpharm Pharmaceuticals S.L.

Avinguda De Barcelona 69 Poligono Industrialde La Fuensanta 08970 Sant Joan Despi SPAIN

Opinion adopted 17/10/2024 Marketing authorisation issued 19/12/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Buprenorphine Neuraxpharm : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (128.78 KB - PDF)

**First published:** 16/05/2025

[View](/en/documents/procedural-steps-after/buprenorphine-neuraxpharm-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

CHMP summary of positive opinion for Buprenorphine Neuraxpharm

Adopted

Reference Number: EMA/CHMP/112129/2024

English (EN) (155.12 KB - PDF)

**First published:** 18/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-buprenorphine-neuraxpharm_en.pdf)

#### News on Buprenorphine Neuraxpharm

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2024) 18/10/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Buprenorphine Neuraxpharm : EPAR - Product information - tracked changes

English (EN) (528.82 KB - DOCX)

**First published:** 16/05/2025

[View](/en/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-400)

български (BG) (541.96 KB - DOCX)

**First published:**

16/05/2025

[View](/bg/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_bg.docx)

español (ES) (498.08 KB - DOCX)

**First published:**

16/05/2025

[View](/es/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1017.5 KB - DOC)

**First published:**

16/05/2025

[View](/cs/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (529.29 KB - DOCX)

**First published:**

16/05/2025

[View](/da/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (621.66 KB - DOCX)

**First published:**

16/05/2025

[View](/de/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (523.73 KB - DOCX)

**First published:**

16/05/2025

[View](/et/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (546.96 KB - DOCX)

**First published:**

16/05/2025

[View](/el/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_el.docx)

français (FR) (537 KB - DOCX)

**First published:**

16/05/2025

[View](/fr/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (536.84 KB - DOCX)

**First published:**

16/05/2025

[View](/hr/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (534.79 KB - DOCX)

**First published:**

16/05/2025

[View](/is/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_is.docx)

italiano (IT) (535.77 KB - DOCX)

**First published:**

16/05/2025

[View](/it/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (533.29 KB - DOCX)

**First published:**

16/05/2025

[View](/lv/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (522.69 KB - DOCX)

**First published:**

16/05/2025

[View](/lt/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (541.58 KB - DOCX)

**First published:**

16/05/2025

[View](/hu/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (533.37 KB - DOCX)

**First published:**

16/05/2025

[View](/mt/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (868 KB - DOC)

**First published:**

16/05/2025

[View](/nl/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (194.79 KB - DOCX)

**First published:**

16/05/2025

[View](/no/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_no.docx)

polski (PL) (536.2 KB - DOCX)

**First published:**

16/05/2025

[View](/pl/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_pl.docx)

português (PT) (520.93 KB - DOCX)

**First published:**

16/05/2025

[View](/pt/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_pt.docx)

română (RO) (259.69 KB - DOCX)

**First published:**

16/05/2025

[View](/ro/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (970.5 KB - DOC)

**First published:**

16/05/2025

[View](/sk/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (523.84 KB - DOCX)

**First published:**

16/05/2025

[View](/sl/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (525.49 KB - DOCX)

**First published:**

16/05/2025

[View](/fi/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (526.52 KB - DOCX)

**First published:**

16/05/2025

[View](/sv/documents/product-information-tracked-changes/buprenorphine-neuraxpharm-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 16/05/2025

## Share this page

[Back to top](#main-content)